Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ascendis Pharma A (ASND) Intangibles: 2020-2024

  • Ascendis Pharma A's Intangibles fell 9.47% to $4.3 million in Q4 2024 from the same period last year, while for Dec 2024 it was $4.3 million, marking a year-over-year decrease of 9.47%. This contributed to the annual value of $4.4 million for FY2024, which is 8.31% down from last year.
  • According to the latest figures from Q4 2024, Ascendis Pharma A's Intangibles is $4.3 million, which was down 9.47% from $4.8 million recorded in Q4 2023.
  • Ascendis Pharma A's 5-year Intangibles high stood at $6.8 million for Q4 2020, and its period low was $4.3 million during Q4 2024.
  • Over the past 3 years, Ascendis Pharma A's median Intangibles value was $4.8 million (recorded in 2023), while the average stood at $5.0 million.
  • Data for Ascendis Pharma A's Intangibles shows a maximum YoY declined of 18.48% (in 2023) over the last 5 years.
  • Ascendis Pharma A's Intangibles (Quarterly) stood at $6.8 million in 2020, then declined by 4.05% to $6.5 million in 2021, then decreased by 10.82% to $5.8 million in 2022, then fell by 18.48% to $4.8 million in 2023, then dropped by 9.47% to $4.3 million in 2024.
  • Its Intangibles was $4.3 million in Q4 2024, compared to $4.8 million in Q4 2023 and $5.8 million in Q4 2022.